Abstracts tagged "Renal disease"

Abstract Number: 2915 • 2015 ACR/ARHP Annual Meeting
The Utility of Lupus Serology in Predicting Outcomes of Renal Transplantation in Lupus Patients: Systematic Review and Analysis of a Large Lupus Cohort
Kristy Yap¹, Murray Urowitz^1,2, Quenby Mahood³, Jorge Medina-Rosas⁴, Arthy Sabapathy⁵, Daeria Lawson⁴, Jiandong Su¹, Dafna Gladman¹ and Zahi Touma¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Library Services, Institute of Work and Health, Toronto, ON, Canada, ⁴Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: To study the utility of lupus serology as a predictor for kidney graft outcome in: a) a systematic review (SR) of the literature and…
Abstract Number: 2995 • 2015 ACR/ARHP Annual Meeting
Genome Wide Analysis in Scleroderma Renal Crisis: Defining Genetic Risk in Patients with RNA Polymerase III Auto-Antibodies
Maria C Fonseca¹, Sandra Guerra¹, Edward Stern^1,2, Svetlana I. Nihtyanova¹, David Abraham³, Aine Burns², Mark Harber² and Christopher P. Denton⁴, ¹Rheumatology, UCL Division of Medicine, London, United Kingdom, ²Nephrology, Royal Free Hospital, London, United Kingdom, ³Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Scleroderma renal crisis (SRC) is a severe complication of systemic sclerosis (SSc). Most SSc cases demonstrate a disease-specific antinuclear antibody including anti-RNA polymerase III…
Abstract Number: 2716 • 2014 ACR/ARHP Annual Meeting
Development of a “Renal Crisis Prevention Card” As an Educational Tool Aimed at Improving Outcomes in High-Risk Patients with Systemic Sclerosis
Lee S. Shapiro^1,2,3, Lesley Ann Saketkoo⁴, Jessica F. Farrell^2,3,5 and Kim Fligelstone⁶, ¹Albany Medical College, Albany, NY, ²Steffens Scleroderma Center, Saratoga Springs, NY, ³The Center for Rheumatology, Albany, NY, ⁴Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ⁵Pharmacy Practice, Albany College of Pharmacy & Health Sciences, Albany, NY, ⁶Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom
Background/Purpose: Scleroderma renal crisis (SRC) is a devastating complication of SSc. The introduction of effective treatment with ACE inhibition (ACE-I) in 1979 dramatically reduced…
Abstract Number: 1912 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Therapy for Rheumatoid Arthritis Patients with Chronic Renal Insufficiency
Shunsuke Mori, Clinical Research Center for Rheumatic Diseases, NHO Kumamoto Saishunsou National Hospital, Kumamoto, Japan
Background/Purpose: Renal involvement is relatively common in rheumatoid arthritis (RA) patients. Recent randomized controlled trials of anti-tumor necrosis factor-α (anti-TNFα) showed that the concomitant administration…
Abstract Number: 813 • 2014 ACR/ARHP Annual Meeting
Long-Term Outcomes of Takayasu’s Arteritis Patients with Renal Artery Involvement
Corisande Baldwin¹, Aladdin Mohammad² and David Jayne³, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Dept. of Rheumatology, Lund University Hospital, Lund University, Lund, Lund, Sweden, ³Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Takayasu's Arteritis (TAK) is a chronic inflammatory large vessel vasculitis characterized by granulomatous inflammation of the aorta and its branches. TAK incidence is 2.6/million…
Abstract Number: 2389 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Survives Introducing The Hemadialysis Longer Than Oral Medicine In AA Amyloidosis Patients With Rheumatoid Arthritis Of Renal Insufficiency
Osamu Saiki¹, Hiroshi Uda¹, Ayumi Matsumoto², Aya Mizumoto³, Tamaki Harada³ and Toshirou Takama³, ¹Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, ²Higashiosaka City General Hospital, Higashiosaka, Japan, ³Nephrology, Higashiosaka City General Hospital, Higashiosaka, Japan
Background/Purpose: In AA amyloidosis patients with RA taking oral medicines such as methotrexate and prednisolone, it is generally accepted that the renal function deteriorates gradually…
Abstract Number: 857 • 2013 ACR/ARHP Annual Meeting
Impact of Urate Lowering Therapy On Renal Disease Progression in Patients With Hyperuricemia
Gerald D. Levy¹, T. Craig Cheetham², Nazia Rashid³ and Fang Niu², ¹Int Med/Rheumatology, Southern California Permanente Medical Group, Downey, CA, ²Pharmacy Analytical Services, Kaiser Permanente, Downey, CA, ³Pharmacy Analytical Services, Kaiser Permanente Southern California, Downey, CA
Background/Purpose: The relationship between elevated serum Uric Acid [sUA] and progression of chronic kidney disease is well established.1-3 There are a several small studies on…
Abstract Number: 2552 • 2012 ACR/ARHP Annual Meeting
Clinically Significant and Biopsy-Documented Renal Involvement in Primary Sjögren’s Syndrome: Clinical Presentation and Outcome
Andreas V. Goules¹, Ioanna P. Tatouli², Alexandros A. Drosos³, Fotini N. Skopouli⁴, Haralampos M. Moutsopoulos⁵ and Athanasios G. Tzioufas⁶, ¹Pathophysiology, National University of Athens, Athens, Greece, ²School of Medicine, National University of Athens, Athens, Greece, ³Rheumatology Clinic, Department of Internal Medicine, Professor of Medicine/Rheumatology, Ioannina, Greece, ⁴Harokopion University, Athens, Greece, ⁵Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, ⁶Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: Primary Sjögren’s syndrome (pSS) may affect kidneys, causing either interstitial nephritis (IN) or glomerulonephritis (GMN). However, overt renal disease in pSS is rare and…
Abstract Number: 2266 • 2012 ACR/ARHP Annual Meeting
Outcome of Renal Transplantation in Lupus Patients with Positive and Negative Serology: Survival of the Graft and Patients After Transplant
Zahi Touma¹, Murray B. Urowitz², Dominique Ibanez² and D. D. Gladman³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) occurs in 50-75% of adults with SLE and up to 20% of LN patients may advance to end stage renal disease…
Abstract Number: 1696 • 2012 ACR/ARHP Annual Meeting
Quantitative Evaluation of Dermal Atrophy by High-Resolution Ultrasonography, Comparing Between Patients Under Long-Term Treatment with Prednisolone or Methylprednisolone
Tim Pottel¹, Christoph Schäfer² and Gernot Keyßer², ¹Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06114 Halle (Saale), Germany, ²Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06120 Halle (Saale), Germany
Background/Purpose: The katabolic effects of a systemic treatment with glucocorticoids can lead to a progressive atrophy of the skin. Clinical observation suggests a more pronounced…
Abstract Number: 816 • 2012 ACR/ARHP Annual Meeting
Glomerular Filtration Rate, Chronic Kidney Disease and Incidence of Physician Diagnosed Gout
Eswar Krishnan, Medicine, Standford University, Palo Alto, CA
Background/Purpose: The kidney is the major organ of urate excretion in humans. Yet, there are few studies that assess whether reduced glomerular filtration and/or kidney…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].